The World Health Organization (WHO) has formed a committee of expert advisors tasked with assessing influenza virus surveillance data, produced by the WHO Global Influenza Surveillance and Response System (GISRS). Based on these assessments, the committee provides guidance on the composition of the upcoming influenza season vaccines. The proposed strains for inclusion in the vaccine production, set to begin shortly, are as follows:
Our projected timeline anticipates vaccine availability by October 2023.
Our team will promptly reach out to confirm your appointment.
Antigen Test (Lateral flow) – All-inclusive price of 15000 yen for the test, consumption tax, English certificate, and consultation. This test will be conducted via nasal swab and will take 15 minutes to process. You will be leaving with a physician-signed document in hand.
PCR Test (Real-time Reverse Transcription) – All-inclusive price of 25000 yen for the test, consumption tax, English certificate, and consultation. This test will be conducted via saliva (or nasopharyngeal swab if required). Samples received by 12:00 noon will be processed by 18:00. Samples received in the afternoon will be processed by 9:00 the following business day. You will be receiving a PDF via email as soon as the laboratory report is ready. This test can be used to shorten the quarantine period when entering Japan.
In an effort to prevent community transmission of respiratory illness (COVID-19), we are launching American Clinic Online services to our established patients. Consultations with physicians will be performed on VSee (a telemedicine platform used by NASA). Medicine will be sent to your home or office without physically visiting our clinic. Please register with the following link and call us using VSee for more information. If you cannot reach us, try our regular number at 03-4405-6210.
Japan National Tourism Organization (JNTO) operates a visitor hotline 24 hours a day, 365 days a year. Call for tourist information or assistance in the case of accidents and emergencies including novel coronavirus(COVID-19). Support is available in English, Chinese, Korean and Japanese.
Shingles is a painful rash caused by reactivation of the chickenpox virus. 99% of people over 50 years of age are living with the virus that causes shingles. One in three people will develop shingles in their lifetime.
SHINGRIX works to boost your body’s protection against shingles (herpes zoster). It is a FDA-approved 2-dose series proven to be up to 90% effective in clinical trials.
It is given as a two-dose series, two months apart.